Lee Pai

FDA Unswayed by Pleas to Retain Breast Ca Indication

• But most patients are not super-responders, the FDA countered. In fact, one in four patients in Genentech's clinical trials stopped using bevacizumab because of the side effects, said Lee Pai-Scherf, MD, a medical officer with the FDA's Oncology Drug Products.
• Date: Jun 28, 2011
• Category: Health
• Source: Google